Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Non-Current Deffered Revenue (2019 - 2021)

Historic Non-Current Deffered Revenue for Strata Critical Medical (SRTAW) over the last 3 years, with Q1 2021 value amounting to $9.6 million.

  • Strata Critical Medical's Non-Current Deffered Revenue changed 0.0% to $9.6 million in Q1 2021 from the same period last year, while for Mar 2021 it was $9.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $9.6 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q1 2021, Strata Critical Medical's Non-Current Deffered Revenue is $9.6 million, which was down 0.0% from $9.6 million recorded in Q4 2020.
  • In the past 5 years, Strata Critical Medical's Non-Current Deffered Revenue registered a high of $9.6 million during Q3 2019, and its lowest value of $9.6 million during Q3 2019.
  • Its 3-year average for Non-Current Deffered Revenue is $9.6 million, with a median of $9.6 million in 2019.
  • Over the last 5 years, Strata Critical Medical's Non-Current Deffered Revenue had its largest YoY gain of 0.0% in 2020, and its largest YoY loss of 0.0% in 2020.
  • Strata Critical Medical's Non-Current Deffered Revenue (Quarter) stood at $9.6 million in 2019, then changed by 0.0% to $9.6 million in 2020, then changed by 0.0% to $9.6 million in 2021.
  • Its Non-Current Deffered Revenue stands at $9.6 million for Q1 2021, versus $9.6 million for Q4 2020 and $9.6 million for Q3 2020.